Drug Database · Clinicians

Sildenafil

Brands (62) Kohagra, Robust S, Andros…Show all

Urological (drugs used in erectile dysfunction); Phosphodiesterase type-5 (PDE-5) inhibitor; and others PH FDA category

Rx · Prescription drug115 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID d905dc8d-917f-4ea3-a4ee-a1ecf6967d4e, version date November 17, 2023 (Viagra · Viatris Specialty LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • VIAGRA is indicated for the treatment of erectile dysfunction.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE VIAGRA is indicated for the treatment of erectile dysfunction. VIAGRA is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED) (1)

Contraindications

4 CONTRAINDICATIONS

  • Administration of VIAGRA to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. VIAGRA was shown to potentiate the hypotensive effect of nitrates (4.1, 7.1, 12.2)
  • Known hypersensitivity to sildenafil or any component of tablet (4.2)
  • Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3) 4.1 Nitrates Consistent with its known effects on the nitric oxide/cGMP pathway [see Clinical Pharmacology (12.1, 12.2)], VIAGRA was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. After patients have taken VIAGRA, it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [see Dosage and Administration (2.3), Drug Interactions (7.1), and Clinical Pharmacology (12.2)]. 4.2 Hypersensitivity Reactions VIAGRA is contraindicated in patients with a known hypersensitivity to sildenafil, as contained in VIAGRA and REVATIO, or any component of the tablet. Hypersensitivity reactions have been reported, including rash and urticaria [see Adverse Reactions (6.1)]. 4.3 Concomitant Guanylate Cyclase (GC) Stimulators Do not use VIAGRA in patients who are using a GC stimulator, such as riociguat. PDE5 inhibitors, including VIAGRA, may potentiate the hypotensive effects of GC stimulators.
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • • For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, VIAGRA may be taken anywhere from 30 minutes to 4 hours before sexual activity (2.1)
  • • Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg (2.1)
  • • Maximum recommended dosing frequency is once per day (2.1)
2.1 Dosage Information

2.1 Dosage Information For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, VIAGRA may be taken anywhere from 30 minutes to 4 hours before sexual activity. The maximum recommended dosing frequency is once per day. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg.

2.2 Use with Food

2.2 Use with Food VIAGRA may be taken with or without food.

2.3 Dosage Adjustments in Specific Situations

2.3 Dosage Adjustments in Specific Situations VIAGRA was shown to potentiate the hypotensive effects of nitrates and its administration in patients who use nitric oxide donors such as organic nitrates or organic nitrites in any form is therefore contraindicated [see Contraindications (4.1), Drug Interactions (7.1), and Clinical Pharmacology (12.2)]. When VIAGRA is co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating VIAGRA treatment and VIAGRA should be initiated at 25 mg [see Warnings and Precautions (5.5), Drug Interactions (7.2), and Clinical Pharmacology (12.2)].

2.4 Dosage Adjustments Due to Drug Interactions Ritonavir

2.4 Dosage Adjustments Due to Drug Interactions Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [see Warnings and Precautions (5.6), Drug Interactions (7.4), and Clinical Pharmacology (12.3)]. CYP3A4 Inhibitors Consider a starting dose of 25 mg in patients treated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin.

Clinical data have shown that co-administration with saquinavir or erythromycin increased plasma levels of sildenafil by about 3 fold [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)].

2.5 Dosage Adjustments in Special Populations

2.5 Dosage Adjustments in Special Populations Consider a starting dose of 25 mg in patients > 65 years, patients with hepatic impairment (e.g., cirrhosis), and patients with severe renal impairment (creatinine clearance <30 mL/minute) because administration of VIAGRA in these patients resulted in higher plasma levels of sildenafil [see Use in Specific Populations (8.5, 8.6, 8.7) and Clinical Pharmacology (12.3)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (use in specific populations, pharmacokinetics)

8.6 Renal Impairment No dose adjustment is required for mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment. In volunteers with severe renal impairment (Clcr<30 mL/min), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (~2 fold), approximately doubling of C max and AUC. A starting dose of 25 mg should be considered in patients with severe renal impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].

Renal Impairment In volunteers with mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose of VIAGRA (50 mg) were not altered. In volunteers with severe (CLcr <30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and C max compared to age-matched volunteers with no renal impairment [see Dosage and Administration (2.5), and Use in Specific Populations (8.6)].

In addition, N-desmethyl metabolite AUC and C max values significantly increased by 200% and 79%, respectively in subjects with severe renal impairment compared to subjects with normal renal function.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for C max and 85% for AUC). The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied. A starting dose of 25 mg should be considered in patients with any degree of hepatic impairment [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use VIAGRA is not indicated for use in pediatric patients. Safety and effectiveness have not been established in pediatric patients.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18-45 years) [see Clinical Pharmacology (12.3)]. Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [see Clinical Pharmacology (12.3)].

Of the total number of subjects in clinical studies of VIAGRA, 18% were 65 years and older, while 2% were 75 years and older. No overall differences in safety or efficacy were observed between older (≥65 years of age) and younger (<65 years of age) subjects. However, since higher plasma levels may increase the incidence of adverse reactions, a starting dose of 25 mg should be considered in older subjects due to the higher systemic exposure [see Dosage and Administration (2.5)].

Dosage forms

Philippines

  • Film-coated tablet: 25 mg, 50 mg, 100 mg
  • Tablet: 25 mg, 50 mg, 100 mg
  • Chewable tablet: 100 mg
  • Orally disintegrating strip: 50 mg

Registered products in the Philippines

115 products registered with the Food and Drug Administration (FDA) Philippines list Sildenafil as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products115
Philippine FDA-registered products for Sildenafil
Package insert
AjenafilSildenafil (as citrate)
100 mg Chewable TabletPVC/PCTFE-Aluminum Blister Pack x 4's (Box of 1's)
Rx
Genepharm SAGreece
Importer: AJ RESEARCH & PHARMA INC.
DR-XY46404
Aug 2, 2028
AndrosSildenafil (as citrate)
100 mg Film-coated TabletBlister Pack x 1's in Polycard Box of 5's
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, INC.
DRP-3051
Nov 5, 2027
AndrosSildenafil (as citrate)
25 mg Film-Coated TabletPolycard of 1's in Blister Foil (Box of 5's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY31057
Jul 9, 2031
AndrosSildenafil (as citrate)
50 mg Film-coated TabletBlister Pack x 1s in Polycard Box of 5's
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, INC.
DRP-3050
Nov 5, 2027
Anexxx-50Sildenafil (as citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Globela Pharma Pvt. Ltd.India
Biocare Lifesciences, Inc.Trader: AMN Life Science Pvt. Ltd.
DRP-4587
Aug 5, 2028
Bignight-100Sildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4’s (Box of 4’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Dima Health Technology, IncorporatedImporter: Ambica International Corporation
DRP-3155-07
Aug 11, 2029
BlupilSildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
11 Asia Pacific International Trading Corp.
DRP-16613-03
May 16, 2030
BlupilSildenafil (as Citrate)
25 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
11 Asia Pacific International Trading Corp.
DRP-16779-03
Jul 10, 2030
BlupilSildenafil (as Citrate)
50 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
11 Asia Pacific International Trading Corp.
DRP-16677-03
Jun 4, 2030
EbadilSildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-16613-04
May 16, 2030
EbadilSildenafil (as Citrate)
25 mg TabletAlu / PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-16779-04
Jul 10, 2030
EbadilSildenafil (as Citrate)
50 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Eba Generisch Trading Inc.
DRP-16677-04
Jun 4, 2030
Erecfil-100Sildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's); Alu/Clear PVC Blister Pack x 4's (Box of 8's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Coporation
DRP-3155
Aug 11, 2029
Erecfil-50Sildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's Box of 4's and 8's
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Coporation
DRP-3157
Aug 11, 2029
Erecmed 100Sildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's and 8's)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-3155-03
Aug 11, 2029
Erecmed 50Sildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's and 8's)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-3157-03
Aug 11, 2029
ErectaSildenafil (As Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 1's)
Rx
Phil. United Pharma Corp.Philippines
Trader: Golden Dale Pharma Corp
DRP-10628
Nov 16, 2026Past listed date
ErectaSildenafil (as citrate)
25 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 1's)
Rx
Phil. United Pharma CorporationCavite
Trader: Golden Dale Pharma Corp.
DRP-11302
Nov 24, 2031
ErectaSildenafil (As Citrate)
50 mg Film-Coated TabletAlu/PVC Film Blister Pack x 4's (Box of 4's)
Rx
Phil. United Pharma CorporationPhilippines
Trader: Golden Dale Pharma Corp.
DRP-13268
Jan 19, 2028
ErectoSildenafil (as Citrate)
100mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's)
Rx
New Myrex Laboratories, Inc.Philippines
—
DRP-6850
Oct 6, 2031
ErectoSildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's)
Rx
New Myrex Laboratories, Inc.Bulacan
—
DRP-6849
Oct 6, 2031
Erefil-100Sildenafil (as citrate)
100 mg Film-Coated TabletAlu-Alu Blister Pack x 8's (Box of 8's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Medhaus Pharma Inc.
DR-XY34895
Sep 3, 2028
ErexilSildenafil (as citrate)
100 mg Film-Coated tabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Akriti Pharmaceuticals Pvt. Ltd.India
Euroasia Pharmaceuticals, Inc.
DRP-12543
Aug 30, 2032
GoRocky S 100Sildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 8's)
Rx
Stallion Laboratories Pvt. Ltd.India
GoRocky Medical Inc.Importer: Ambica International Corporation
DRP-3155-05
Aug 11, 2029
GoRocky S 50Sildenafil (as citrate)
50 mg Film-Coated TabletAlu / Clear PVC Blister Pack x 4's (Box of 8's)
Rx
Stallion Laboratories Pvt. Ltd.India
GoRocky Medical Inc.Importer: Ambica International Corporation
DRP-3157-05
Aug 11, 2029
GreatafilSildenafil (as Citrate)
50 mg Film-Coated TabletAlu-PVC Blister Pack of 4's in a Box (Box of 4's)
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DR-XY40905
May 18, 2027
Greatafil MaxSildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's in Individual Box (Box of 4's)
Rx
Flamingo Pharmaceuticals Ltd.India
Hexagon Pharmaceuticals
DR-XY40309
Nov 17, 2031
HydenexSildenafil (as Citrate)
50 mg TabletAlu/PVC Blister Pack x 10's (Box of 10's)
Rx
Compact Pharmaceutical CorporationPhilippines
ZEUS RESOURCES, INC.
DR-XY43127
Feb 20, 2029
KadagraSildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister pack x 4's (Box of 4's)
Rx
Swiss Pharma Pvt. Ltd.India
Sahar International Trading Inc.Trader: SRI Pharmacare
DR-XY40223
Oct 20, 2031
KadagraSildenafil (as Citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4's *Box of 4's)
Rx
Swiss Pharma Pvt. Ltd.India
Sahar International Trading, Inc.Trader: SRI Pharmacare
DRP-7285
Mar 27, 2028
KohagraSildenafil (as Citrate)
100 mg Film Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Centurion Remedies Pvt. LtdIndia
Tobie Pharma, IncImporter: Philgen Pharmaceuticals Inc
DRP-14302
Apr 30, 2028
KohagraSildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Centurion Remedies Pvt. Ltd.India
Tobie Pharma, Inc.Importer: Philgen Pharmaceuticals Inc.
DR-XY41986
Apr 30, 2028
KohagraSildenafil (as Citrate)
25 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Centurion Remedies Pvt. Ltd.India
Tobie Pharma Inc.Importer: Philgen Pharmaceuticals Inc.
DR-XY42161
Jun 25, 2028
KohagraSildenafil (as Citrate)
25 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Centurion Remedies Pvt. Ltd.India
Tobie Pharma, IncImporter: Philgen Pharmaceuticals, Inc.
DRP-14301
Jun 25, 2028
KohagraSildenafil (as Citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Centurion Remedies Pvt. Ltd.India
Tobie Pharma, Inc.Importer: Philgen Pharmaceuticals Inc.
DR-XY41987
Apr 30, 2028
KohagraSildenafil (as Citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Centurion Remedies Pvt. Ltd.India
Tobie Pharma, IncImporter: Philgen Pharmaceuticals Inc
DRP-14270
Apr 30, 2028
MatonSildenafil (as Citrate)
100 mg Film-Coated TabletAlu / PVC Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Triple 888 Medical and Pharma Inc.
DRP-16613-05
May 16, 2030
Neo-UpSildenafil (as citrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 8's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DR-XY35058
Oct 20, 2028
Neo-UpSildenafil (as citrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DR-XY35059
Oct 20, 2028
NoneSildenafil (as citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Jubilant Generics Ltd.India
RiteMED Phils., Inc.
DR-XY41997
May 3, 2031
NoneSildenafil (as citrate)
100 mg Film-Coated TabletClear PVC/Alu Blister Pack x 4's (Box of 4's)
Rx
Fareva AmboiseFrance
Philusa CorporationImporter: PF OFG Philippines Inc.
DRP-2073-01
Mar 23, 2027
NoneSildenafil (as citrate)
100 mg Film-coated TabletBlister Pack x 1's in Polycard (Box of 5's)
Rx
Amherst Laboratories, Inc.Philippines
RiteMed Phils., Inc.
DRP-3051-02
Nov 5, 2027
NoneSildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Brawn Laboratories Ltd.India
International Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-5190-01
Feb 17, 2029
NoneSildenafil (as citrate)
100 mg TabletAlu/PVC Blister Pack x 10's (Box of 10's)
Rx
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma, Inc.
DRP-3965-02
Feb 3, 2030
NoneSildenafil (as citrate)
50 mg Film-Coated TabletClear PVC/Alu Blister Pack x 4's (Box of 4's)
Rx
Fareva AmboiseFrance
Philusa CorporationImporter: PF OFG Philippines Inc.
DRP-2072-01
Mar 23, 2027
NoneSildenafil (as citrate)
50 mg Film-coated TabletBlister Pack x 1's in Polycard Box of 5's
Rx
Amherst Laboratories, Inc.Philippines
Ritemed Phils., Inc.
DRP-3050-02
Nov 5, 2027
NoneSildenafil (as citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4’s (Box of 4’s)
Rx
Brawn Laboratories LimitedIndia
International Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-4511-02
Jul 18, 2028
Onagra-100Sildenafil (as citrate)
100 mg Film Coated TabletAlu/PVC Blister Pack x 4's and 10's (Box of 4's and 10's)
Rx
Sai Mirra Innopharm Pvt. Ltd.India
EON Pharmatek Inc.
DR-XY48540
Dec 27, 2027
Onagra-100Sildenafil (as citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's and 10's (Box of 4's and 10's)
Rx
Sai Mirra Innopharm Pvt. Ltd.India
Eon Pharmatek Inc.
DRP-17280
Dec 27, 2027
Onagra-50Sildenafil (as citrate)
50 mg Film-Coated TabletAlu/ PVC Blister Pack x 4's and 10's (Box of 4's and 10's)
Rx
Sai Mirra Innopharm Pvt. Ltd.India
Eon Pharmatek Inc.
DRP-17281
Dec 27, 2027
OyatSildenafil (as Citrate)
50 mg TabletAlu / PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Triple 888 Medical and Pharma Inc.
DRP-16677-05
Jun 4, 2030
Peak 100Sildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Dima Health Technology, IncorporatedImporter: Ambica International Corporation
DRP-3155-06
Aug 11, 2029
PEAK 50Sildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Dima Health Technology, IncorporatedImporter: Ambica International Corporation
DRP-3157-07
Aug 11, 2029
Penegra 100Sildenafil (as citrate)
100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 4's); Alu/PVC/PVDC Blister Pack x 10's (Box of 100's); Alu/PVC/PVDC Blister Pack x 10's (Box of 4's as physician's sample); Alu/PVC/PVDC Blister Pack x 10's (Box of 10's as physician's sample)
Rx
Cadila Healthcare LimitedIndia
Zydus Healthcare Philippines, Inc.
DRP-7595
Aug 8, 2028
Penegra 50Sildenafil (as Citrate)
50 mg Film Coated TabletClear PVC/Alu Blister Pack (Box of 4's); Clear PVC/Alu Blister Pack (Box of 100's); Clear PVC/Alu Blister Pack (Box of 4's as Physician's Sample); Clear PVC/Alu Blister Pack (Box of 10's as Physician's Sample)
Rx
Cadila Healthcare LimitedIndia
Zydus Healthcare Philippines, Inc.
DRP-7596
Oct 16, 2028
PlefilSildenafil (as Citrate)
100 mg Film Coated TabletPVC/Alu Blister Pack x 4's (Box of 4's)
Rx
Saga Lifesciences LimitedIndia
Hexagon Pharmaceuticals
DR-XY39617
Oct 8, 2029
PlefilSildenafil (as Citrate)
50 mg Film-Coated TabletPVC/Alu Blister Pack x 4's (Box of 4's)
Rx
Saga LaboratoriesIndia
Hexagon Pharmaceuticals
DR-XY39668
Jul 19, 2031
RapidilSildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-16613-01
May 16, 2030
RapidilSildenafil (as Citrate)
25 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-16779-01
Jul 10, 2030
RapidilSildenafil (as Citrate)
50 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
St. Raphael Archangel Pharmaceutical Product Distribution
DRP-16677-01
Jul 4, 2030
REGISIL 100Sildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Regimed Pharmaceutical Distributor
DRP-16613-02
May 16, 2030
REGISIL 25Sildenafil (as Citrate)
25 mg TabletAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Regimed Pharmaceutical Distributor
DRP-16779-02
Jul 10, 2030
Regisil 50Sildenafil (as Citrate)
50 mg TabletAlu / PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
Regimed Pharmaceutical Distributor
DRP-16677-02
Jun 4, 2030
RetafilSildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4’s (Box of 8’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Reta DrugImporter: Ambica International Corporation
DRP-3155-02
Aug 11, 2029
RetafilSildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4’s (Box of 8’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Reta DrugImporter: Ambica International Corporation
DRP-3157-02
Aug 11, 2029
Robust PlusSildenafil (as citrate)
25 mg Film-Coated TabletAlu/PVC Film Blister Pack x 4's (Box of 4's and 8's); Alu/PVC Film Blister Pack x 10's (Box of 10's and 20's)
Rx
Phil. United Pharma CorporationPhilippines
Trader: A.T.C Health Care International Corp.
DRP-11301
Nov 24, 2031
Robust SSildenafil (As Citrate)
100 mg Film-Coated TabletAlu/PVC Film Blister Pack x 2's (Box of 2's) + Alu/PVC Film Blister Pack x 4's (Box of 4's and 8's) + Alu/PVC Film Blister Pack x 10's (Box of 10's and 20's)
Rx
Phil. United Pharma Corp.Philippines
Trader: A.T.C. Health Care International Corp.
DRP-10627
Dec 7, 2026
Robust SSildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's)
Rx
Stallion Laboratories Pvt. Ltd.India
ATC Healthcare International Corp.Importer: Ambica International Corporation
DRP-3155-01
Aug 11, 2029
Robust SSildenafil (As Citrate)
50 mg Film-Coated TabletAlu/PVC Film Clear Blister Pack x 4's (Box of 4's)
Rx
Phil. United Pharma CorporationPhilippines
Trader: A.T.C. Health Care International Corp.
DRP--13154
Dec 9, 2027
Robust SSildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's Box of 4's
Rx
Stallion Laboratories Pvt. Ltd.India
ATC Healthcare International Corp.Importer: Ambica International Corporation
DRP-3157-01
Aug 11, 2029
SeregraSildenafil (as citrate)
50 mg Film-Coated TabletAlu/ PVC Blister Pack x 4's (Box of 4's)
Rx
Bal Pharma LimitedIndia
ECE Pharmaceuticals, Inc.Importer: Pharmakon Biotec Inc.
DRP-7624
Oct 14, 2028
SiagraSildenafil (As Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of l's)
Rx
Phil. United Pharma Corp.Philippines
Trader: Docteur's Choice Corporation
DRP-10629
Nov 16, 2026Past listed date
SiagraSildenafil (as citrate)
25 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 1's)
Rx
Phil. United Pharma CorporationCavite
Trader: Docteur's Choice Corporation
DRP-11303
Nov 24, 2031
SiagraSildenafil (As Citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Phil. United Pharma CorporationPhilippines
Trader: Golden Dale Pharma Corp.
DRP-13276
Jan 19, 2028
Silaphil-100Sildenafil (as Citrate)
100 mg Film Coated TabletAlu/PVC blister pack X 4's (Box of 4's)
Rx
Ratnatris Pharmaceuticals Pvt. LtdIndia
AMB HK Enterprises Inc.Trader: N/A
DRP-18027
Apr 28, 2031
Silaphil-50Sildenafil (as Citrate)
50 mg Film Coated TabletAlu-PVC blister Pack x 4's (Box of 4's)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises Inc.
DRP-18028
Apr 28, 2031
Sildafil 100Sildenafil (as citrate)
100mg Film Coated TabletAlu/PVC blister pack x 4's Box of 12's
Rx
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine Branch Office
DRP-8165
Apr 17, 2029
SildefarSildenafil (As Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (individually boxed) x 10's (Box of 40's)
Rx
Zim Laboratories LimitedIndia
Pharmakon Biotec Inc.
DR-XY48146
Jul 1, 2027
SildegraSildenafil (as Citrate)
50 mg Film-Coated TabletBlister pack x 4's (Box of 4's)
Rx
Intas Pharmaceuticals LimitedIndia
Phil Pharmawealth, Inc.
DR-XY34668
Jun 26, 2028
SildemaxSildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's)
Rx
Stallion Laboratories Pvt. Ltd.India
Sigma Medical Solution Trading Co., Inc.Importer: Ambica International Corporation
DRP-3157-06
Aug 11, 2029
SildoraSildenafil (as citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Synmedic LaboratoriesIndia
One Pharma Marketing Inc.
DR-XY39730
Jun 6, 2028
Silrec 50Sildenafil (as citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4’s (Box of 4’s)
Rx
Brawn Laboratories LimitedIndia
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4511-01
Jul 18, 2028
SixtafilSildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's. 50's and 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-16613
May 16, 2030
SixtafilSildenafil (as Citrate)
25 mg Film-Coated TabletAlu/PVC Clear Blister Pack x 10’s (Box of 30’s, 50’s & 100’s)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-16779
Jul 10, 2030
SixtafilSildenafil (as Citrate)
50 mg Film-Coated TabletAlu/PVC Clear Blister Pack x 10’s (Box of 30’s, 50’s & 100’s)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
—
DRP-16677
Jun 4, 2030
SpeedgraSildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's)
Rx
Bal Pharma LimitedIndia
Endure Medical, Inc.Importer: Singapore Genebio, Inc.
DR-XY41797
Mar 13, 2031
SpeedgraSildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack (Box of 1's)
Rx
Bal Pharma LimitedIndia
Endure Medical Inc.Importer: Singapore Genebio Inc.
DR-XY42355
Aug 1, 2028
Spiagra-100Sildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's)
Rx
Centurion Remedies Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-4329
Mar 25, 2028
SudeltaSildenafil (as citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4’s (Box of 4’s)
Rx
Brawn Laboratories LimitedIndia
Mc Graw Pharma IncImporter: Ambica International Corporation
DRP-4511-03
Jul 18, 2028
TigerfilSildenafil (as citrate)
50 mg TabletAlu/Clear Blister Pack x 4's (Box of 4's)
Rx
Sandoz Private LimitedIndia
Sandoz Philippines Corporation
DRP-3290
Oct 3, 2031
TrurexionSildenafil (as citrate)
100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's)
Rx
Stallion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-3155-04
Aug 11, 2029
TrurexionSildenafil (as citrate)
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's)
Rx
Stallion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-3157-04
Aug 11, 2029
UnbrandedSildenafil (as citrate)
100 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 8's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DRP-10211
Sep 14, 2031
UnbrandedSildenafil (as citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 1's)
Rx
Phil. United Pharma Corp.Cavite
—
DRP-10665
Nov 9, 2031
UnbrandedSildenafil (as citrate)
50 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 8's)
Rx
Lloyd Laboratories, Inc.Bulacan
—
DRP-10212
Sep 14, 2031
UnbrandedSildenafil (as citrate)
50 mg film-coated tabletAlu/Clear PVC Blister Pack x 4's (Box of 4's)
Rx
Diamond Laboratories Inc.Philippines
Tobie Pharma, Inc.
DRP-12158
Jun 24, 2032
UnbrandedSildenafil (as citrate)
50 mg TabletAlu/Aclar Blister Pack x 4's (Box of 4's)
Rx
Sandoz Private LimitedIndia
RiteMed Phils., Inc.Importer: Sandoz Philippines Corporation
DRP-3290-01
Oct 3, 2031
ViagraSildenafil (as citrate)
100 mg Film-Coated Tablet
Rx
FAREVA AMBOISE
Importer: PF OFG Philippines Inc.
DRP-2073
Mar 23, 2027
ViagraSildenafil (as citrate)
25 mg Film-Coated TabletPVC/PE Aluminum Foil Blister Pack x 4's (Box of 4's)
Rx
Fareva AmboiseFrance
Importer: Viatris, Inc.
DRP-3434
Apr 27, 2037
ViagraSildenafil (as citrate)
50 mg Film-Coated Tablet
Rx
FAREVA AMBOISE
Importer: PF OFG Philippines Inc.
DRP-2072
Mar 23, 2027
Viakfil -50Sildenafil (as Citrate)
50 mg TabletAlu / PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's)
Rx
Azarias Pharmaceutical Laboratories Inc.Philippines
999-Seth Pharmaceutical Inc.
DRP-16677-06
Jun 4, 2030
ViastarSildenafil (as citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4’s (Box of 4’s)
Rx
Bal Pharma Limited (Unit-I)India
Rule Med Pharma Corp.Importer: Pharmakon Biotec Inc.
DRP-7623-04
Oct 14, 2028
ViastarSildenafil (as citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Bal Pharma Limited (Unit-I)India
Rule Med Pharma Corp.Importer: Pharmakon Biotec Inc.
DRP-7624-02
Oct 14, 2028
VigrasilSildenafil (as Citrate)
100 mg TabletAlu/PVC Blister Pack x 10"s (Box of 10's)
Rx
Drugmaker’s Laboratories Inc.Philippines
—
DRP-3965
Feb 3, 2030
Vivax-100Sildenafil (as Citrate)
100 mg Film-Coated TabletAlu/PVC Blister Pack x 4's (Box of 4's)
Rx
Brawn Laboratories Ltd.India
Ambica International Corporation
DRP-5190
Feb 17, 2029
Vivax-50Sildenafil (as citrate)
50 mg Film-Coated TabletAlu/PVC Blister Pack x 4’s (Box of 4’s)
Rx
Brawn Laboratories LimitedIndia
Ambica International Corporation
DRP-4511
Jul 18, 2028
Wingora 50Sildenafil (as Citrate)
50 mg Film Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's)
Rx
Meyer Organics Pvt. Ltd.India
KHRIZ PHARMA TRADING INC.
DR-XY41538
Dec 26, 2027
ZildenSildenafil (as citrate)
100 mg Film-Coated TabletPVC-PVDC/Alu Blister Pack x 4's (Box of 60's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Pascual Pharma Corporation.
DR-XY48849
Aug 16, 2028
ZildenSildenafil citrate
50 mg Film-coated TabletAlu/Clear PVC Blister Pack x 10's Box of 10's and 60's
Rx
Pascual Laboratories, Inc.Philippines
Trader: Pascual Pharma Corp.
DR-XY37216
Dec 18, 2029
ZildenSildenafil Citrate
50 mg Film-Coated TabletPVC-PVDC/Alu Blister Pack x 4's (Box of 60's)
Rx
Interphil Laboratories, Inc.Philippines
Trader: Pascual Pharma Corporation
DR-XY48856
Aug 23, 2028
(no brand name)Sildenafil (as citrate)
100 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Diamond Laboratories Inc.Philippines
RichGem Pharma Inc.
DRP-13849
May 2, 2028
(no brand name)Sildenafil (As Citrate)
25 mg FILM-COATED TABLETAlu/PVC Blister Pack x 4's (Box of 1's)
Rx
Phil. United Pharma Corp.Philippines
—
DRP-11300
Nov 24, 2026
(no brand name)Sildenafil (as citrate)
25 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 4's (Box of 4's)
Rx
Diamond Laboratories Inc.Philippines
RichGem Pharma Inc.
DRP-14586
Oct 19, 2028
(no brand name)Sildenafil (As Citrate)
50 mg Film-Coated TabletAlu/PVC Film Blister Pack x 4's (Box of 4's)
Rx
Phil. United Pharma CorporationPhilippines
—
DRP-13197
Dec 23, 2027
(no brand name)Sildenafil Citrate
50 mg Orally Disintegrating StripAluminum foil strip (Box of 10's)
Rx
Zim Laboratories LimitedIndia
Onesource Pharma Solutions, Inc.
DR-XY48249
Aug 2, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS VIAGRA is supplied as blue, rounded diamond shaped film-coated tablets containing sildenafil citrate equivalent to 25 mg, 50 mg, or 100 mg of sildenafil. Tablets are debossed with “VIAGRA” on one side and “VGR 25”, “VGR 50” or “VGR 100” on the other to indicate the dosage strengths. Tablets: 25 mg, 50 mg, 100 mg (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Patients should not use VIAGRA if sexual activity is inadvisable due to cardiovascular status (5.1)
  • • Patients should seek emergency treatment if an erection lasts >4 hours. Use VIAGRA with caution in patients predisposed to priapism (5.2)
  • • Patients should stop VIAGRA and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). VIAGRA should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a “crowded” optic disc may also be at an increased risk of NAION. (5.3)
  • • Patients should stop VIAGRA and seek prompt medical attention in the event of sudden decrease or loss of hearing (5.4)
  • • Caution is advised when VIAGRA is co-administered with alpha-blockers or anti-hypertensives. Concomitant use may lead to hypotension (5.5)
  • • Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures. In patients taking strong CYP inhibitors, such as ritonavir, sildenafil exposure is increased. Decrease in VIAGRA dosage is recommended (2.4, 5.6)
5.1 Cardiovascular

5.1 Cardiovascular There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Therefore, treatments for erectile dysfunction, including VIAGRA, should not be generally used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status.

The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following a complete medical assessment. VIAGRA has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg), [see Clinical Pharmacology (12.2)].

While this normally would be expected to be of little consequence in most patients, prior to prescribing VIAGRA, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. Use with caution in patients with the following underlying conditions which can be particularly sensitive to the actions of vasodilators including VIAGRA – those with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure.

There are no controlled clinical data on the safety or efficacy of VIAGRA in the following groups; if prescribed, this should be done with caution.

  • Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months;
  • Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg);
  • Patients with cardiac failure or coronary artery disease causing unstable angina.
5.2 Prolonged Erection and Priapism

5.2 Prolonged Erection and Priapism Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of VIAGRA. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance.

If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. VIAGRA should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia).

However, there are no controlled clinical data on the safety or efficacy of VIAGRA in patients with sickle cell or related anemias.

5.3 Effects on the Eye

5.3 Effects on the Eye Physicians should advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including VIAGRA, and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal association with the use of all PDE5 inhibitors.

Based on published literature, the annual incidence of NAION is 2.5-11.8 cases per 100,000 in males aged ≥ 50. An observational case-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period.

The results suggest an approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). A similar study reported a consistent result, with a risk estimate of 2.27 (95% CI 0.99, 5.20). Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.

Neither the rare post-marketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION [see Adverse Reactions (6.2)]. Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors.

Individuals who have already experienced NAION are at increased risk of NAION recurrence. Therefore, PDE5 inhibitors, including VIAGRA, should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including VIAGRA, for this uncommon condition.

There are no controlled clinical data on the safety or efficacy of VIAGRA in patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); if prescribed, this should be done with caution.

5.4 Hearing Loss

5.4 Hearing Loss Physicians should advise patients to stop taking PDE5 inhibitors, including VIAGRA, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including VIAGRA.

It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.1, 6.2)].

5.5 Hypotension

5.5 Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives Alpha-blockers Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including VIAGRA, and alpha-adrenergic blocking agents are both vasodilators with blood pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may occur.

In some patients, concomitant use of these two drug classes can lower blood pressure significantly [see Drug Interactions (7.2) and Clinical Pharmacology (12.2)] leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting). Consideration should be given to the following:

  • Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor.
  • In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see Dosage and Administration (2.3)].
  • In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor.
  • Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs. Anti-hypertensives VIAGRA has systemic vasodilatory properties and may further lower blood pressure in patients taking anti-hypertensive medications. In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and VIAGRA, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions (7.3) and Clinical Pharmacology (12.2)].
5.6 Adverse Reactions with the Concomitant Use of Ritonavir

5.6 Adverse Reactions with the Concomitant Use of Ritonavir The concomitant administration of the protease inhibitor ritonavir substantially increases serum concentrations of sildenafil (11-fold increase in AUC). If VIAGRA is prescribed to patients taking ritonavir, caution should be used. Data from subjects exposed to high systemic levels of sildenafil are limited.

Decreased blood pressure, syncope, and prolonged erection were reported in some healthy volunteers exposed to high doses of sildenafil (200-800 mg). To decrease the chance of adverse reactions in patients taking ritonavir, a decrease in sildenafil dosage is recommended [see Dosage and Administration (2.4), Drug Interactions (7.4), and Clinical Pharmacology (12.3)].

5.7 Combination with Other PDE5 Inhibitors or Other Erectile Dysfunction Therapies

5.7 Combination with Other PDE5 Inhibitors or Other Erectile Dysfunction Therapies The safety and efficacy of combinations of VIAGRA with other PDE5 Inhibitors, including REVATIO or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied. Such combinations may further lower blood pressure.

Therefore, the use of such combinations is not recommended.

5.8 Effects on Bleeding

5.8 Effects on Bleeding There have been postmarketing reports of bleeding events in patients who have taken VIAGRA. A causal relationship between VIAGRA and these events has not been established. In humans, VIAGRA has no effect on bleeding time when taken alone or with aspirin. However, in vitro studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor).

In addition, the combination of heparin and VIAGRA had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans. The safety of VIAGRA is unknown in patients with bleeding disorders and patients with active peptic ulceration.

5.9 Counseling Patients About Sexually Transmitted Diseases

5.9 Counseling Patients About Sexually Transmitted Diseases The use of VIAGRA offers no protection against sexually transmitted diseases. Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), may be considered.

Drug interactions

Drug interactions (US label) US FDA label
  • • VIAGRA can potentiate the hypotensive effects of nitrates, alpha-blockers, and anti-hypertensives (4.1, 5.5, 7.1, 7.2, 7.3, 12.2)
  • • With concomitant use of alpha-blockers, initiate VIAGRA at 25 mg dose (2.3)
  • • CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin): Increase VIAGRA exposure (2.4, 7.4, 12.3)
  • ▪ Ritonavir: Do not exceed a maximum single dose of 25 mg in a 48 hour period (2.4, 5.6)
  • ▪ Erythromycin or strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, saquinavir): Consider a starting dose of 25 mg (2.4, 7.4)
7.1 Nitrates Administration

7.1 Nitrates Administration of VIAGRA with nitric oxide donors such as organic nitrates or organic nitrites in any form is contraindicated. Consistent with its known effects on the nitric oxide/cGMP pathway, VIAGRA was shown to potentiate the hypotensive effects of nitrates [see Dosage and Administration (2.3), Contraindications (4.1), Clinical Pharmacology (12.2)].

7.2 Alpha-blockers

7.2 Alpha-blockers Use caution when co-administering alpha-blockers with VIAGRA because of potential additive blood pressure-lowering effects. When VIAGRA is co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating VIAGRA treatment and VIAGRA should be initiated at the lowest dose [see Dosage and Administration (2.3), Warnings and Precautions (5.5), Clinical Pharmacology (12.2)].

7.3 Amlodipine When

7.3 Amlodipine When VIAGRA 100 mg was co-administered with amlodipine (5 mg or 10 mg) to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic [see Warnings and Precautions (5.5), Clinical Pharmacology (12.2)].

7.4 Ritonavir and Other CYP3A4 Inhibitors

7.4 Ritonavir and Other CYP3A4 Inhibitors Co-administration of ritonavir, a strong CYP3A4 inhibitor, greatly increased the systemic exposure of sildenafil (11-fold increase in AUC). It is therefore recommended not to exceed a maximum single dose of 25 mg of VIAGRA in a 48 hour period [see Dosage and Administration (2.4), Warnings and Precautions (5.6), Clinical Pharmacology (12.3)].

Co-administration of erythromycin, a moderate CYP3A4 inhibitor, resulted in 160% and 182% increases in sildenafil C max and AUC, respectively. Co-administration of saquinavir, a strong CYP3A4 inhibitor, resulted in 140% and 210% increases in sildenafil C max and AUC, respectively. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole could be expected to have greater effects than seen with saquinavir.

A starting dose of 25 mg of VIAGRA should be considered in patients taking erythromycin or strong CYP3A4 inhibitors (such as saquinavir, ketoconazole, itraconazole) [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)].

7.5 Alcohol

7.5 Alcohol In a drug-drug interaction study sildenafil 50 mg given with alcohol 0.5 g/kg in which mean maximum blood alcohol levels of 0.08% was achieved, sildenafil did not potentiate the hypotensive effect of alcohol in healthy volunteers [see Clinical Pharmacology (12.2)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

It is eliminated predominantly by hepatic metabolism (mainly CYP3A4) and is converted to an active metabolite with properties similar to the parent, sildenafil.

Metabolism and Excretion Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes.

Drug Interaction Studies Effects of Other Drugs on VIAGRA Sildenafil metabolism is principally mediated by CYP3A4 (major route) and CYP2C9 (minor route).

The concomitant use of erythromycin or strong CYP3A4 inhibitors (e.g., saquinavir, ketoconazole, itraconazole) as well as the nonspecific CYP inhibitor, cimetidine, is associated with increased plasma levels of sildenafil [ see Dosage and Administration (2.4) ].

When a single 100 mg dose of VIAGRA was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 160% increase in sildenafil C max and a 182% increase in sildenafil AUC.

In addition, in a study performed in healthy male volunteers, co-administration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with VIAGRA (100 mg single dose) resulted in a 140% increase in sildenafil C max and a 210% increase in sildenafil AUC.

A stronger CYP3A4 inhibitor such as ketoconazole or itraconazole could be expected to have greater effect than that seen with saquinavir.

Population pharmacokinetic data from patients in clinical trials also indicated a reduction in sildenafil clearance when it was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine) [ see Dosage and Administration (2.4) and Drug Interactions (7.4) ].

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following are discussed in more detail in other sections of the labeling: • Cardiovascular [see Warnings and Precautions (5.1)] • Prolonged Erection and Priapism [see Warnings and Precautions (5.2)] • Effects on the Eye [see Warnings and Precautions (5.3)] • Hearing Loss [see Warnings and Precautions (5.4)] • Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [see Warnings and Precautions (5.5)] • Adverse Reactions with the Concomitant Use of Ritonavir [see Warnings and Precautions (5.6)] • Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [see Warnings and Precautions (5.7)] • Effects on Bleeding [see Warnings and Precautions (5.8)] • Counseling Patients About Sexually Transmitted Diseases [see Warnings and Precautions (5.9)] The most common adverse reactions reported in clinical trials (≥ 2%) are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash. Most common adverse reactions (≥ 2%) include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Viatris at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. VIAGRA was administered to over 3700 patients (aged 19-87 years) during pre-marketing clinical trials worldwide.

Over 550 patients were treated for longer than one year. In placebo-controlled clinical studies, the discontinuation rate due to adverse reactions for VIAGRA (2.5%) was not significantly different from placebo (2.3%). In fixed-dose studies, the incidence of some adverse reactions increased with dose. The type of adverse reactions in flexible-dose studies, which reflect the recommended dosage regimen, was similar to that for fixed-dose studies.

At doses above the recommended dose range, adverse reactions were similar to those detailed in Table 1 below but generally were reported more frequently. Table 1. Adverse Reactions Reported by ≥2% of Patients Treated with VIAGRA and More Frequent than Placebo in Fixed-Dose Phase II/III Studies Adverse Reaction 25 mg (n=312) 50 mg (n=511) 100 mg (n=506) Placebo (n=607) Headache 16% 21% 28% 7% Flushing 10% 19% 18% 2% Dyspepsia 3% 9% 17% 2% Abnormal Vision Abnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light, or blurred vision. 1% 2% 11% 1% Nasal Congestion 4% 4% 9% 2% Back Pain 3% 4% 4% 2% Myalgia 2% 2% 4% 1% Nausea 2% 3% 3% 1% Dizziness 3% 4% 3% 2% Rash 1% 2% 3% 1% When VIAGRA was taken as recommended (on an as-needed basis) in flexible-dose, placebo-controlled clinical trials of two to twenty-six weeks duration, patients took VIAGRA at least once weekly, and the following adverse reactions were reported: Table 2.

Adverse Reactions Reported by ≥2% of Patients Treated with VIAGRA and More Frequent than Placebo in Flexible-Dose Phase II/III Studies Adverse Reaction VIAGRA PLACEBO N=734 N=725 Headache 16% 4% Flushing 10% 1% Dyspepsia 7% 2% Nasal Congestion 4% 2% Abnormal Vision Abnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal vision. 3% 0% Back Pain 2% 2% Dizziness 2% 1% Rash 2% 1% The following events occurred in <2% of patients in controlled clinical trials; a causal relationship to VIAGRA is uncertain.

Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful: Body as a Whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury. Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, palpitation, hypotension, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy.

Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal hemorrhage, gingivitis. Hemic and Lymphatic: anemia and leukopenia. Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia.

Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain, myasthenia, synovitis. Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, somnolence, abnormal dreams, reflexes decreased, hypesthesia. Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased.

Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis. Special Senses: sudden decrease or loss of hearing, mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, ear pain, eye hemorrhage, cataract, dry eyes. Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary incontinence, abnormal ejaculation, genital edema and anorgasmia.

Analysis of the safety database from controlled clinical trials showed no apparent difference in adverse reactions in patients taking VIAGRA with and without anti-hypertensive medication. This analysis was performed retrospectively, and was not powered to detect any pre-specified difference in adverse reactions.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of VIAGRA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion either due to their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors.

Cardiovascular and Cerebrovascular Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of VIAGRA. Most, but not all, of these patients had preexisting cardiovascular risk factors.

Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of VIAGRA without sexual activity. Others were reported to have occurred hours to days after the use of VIAGRA and sexual activity. It is not possible to determine whether these events are related directly to VIAGRA, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors [see Warnings and Precautions (5.1) and Patient Counseling Information (17)].

Hemic and Lymphatic: vaso-occlusive crisis: In a small, prematurely terminated study of REVATIO (sildenafil) in patients with pulmonary arterial hypertension (PAH) secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported in patients who received sildenafil than in those randomized to placebo. The clinical relevance of this finding to men treated with VIAGRA for ED is not known.

Nervous: seizure, seizure recurrence, anxiety, and transient global amnesia. Respiratory: epistaxis Special senses Hearing: Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including VIAGRA. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events.

In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of VIAGRA, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.4) and Patient Counseling Information (17)].

Ocular: diplopia, temporary vision loss/decreased vision, ocular redness or bloodshot appearance, ocular burning, ocular swelling/pressure, increased intraocular pressure, retinal edema, retinal vascular disease or bleeding, and vitreous traction/detachment. Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported rarely post-marketing in temporal association with the use of phosphodiesterase type 5 (PDE5) inhibitors, including VIAGRA.

Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]. Urogenital: prolonged erection, priapism [see Warnings and Precautions (5.2) and Patient Counseling Information (17)], and hematuria.

Adverse reaction frequency tables (US label) US FDA label
Table 1. Adverse Reactions Reported by ≥2% of Patients Treated with VIAGRA and More Frequent than Placebo in Fixed-Dose Phase II/III Studies
Adverse Reaction25 mg (n=312)50 mg (n=511)100 mg (n=506)Placebo (n=607)
Headache16%21%28%7%
Flushing10%19%18%2%
Dyspepsia3%9%17%2%
Abnormal VisionAbnormal Vision: Mild to moderate in severity and transient, predominantly color tinge to vision, but also increased sensitivity to light, or blurred vision.1%2%11%1%
Nasal Congestion4%4%9%2%
Back Pain3%4%4%2%
Myalgia2%2%4%1%
Nausea2%3%3%1%
Dizziness3%4%3%2%
Rash1%2%3%1%
Table 2. Adverse Reactions Reported by ≥2% of Patients Treated with VIAGRA and More Frequent than Placebo in Flexible-Dose Phase II/III Studies
Adverse ReactionVIAGRAPLACEBO
N=734N=725
Headache16%4%
Flushing10%1%
Dyspepsia7%2%
Nasal Congestion4%2%
Abnormal VisionAbnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal vision.3%0%
Back Pain2%2%
Dizziness2%1%
Rash2%1%

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary VIAGRA is not indicated for use in females. There are no data with the use of VIAGRA in pregnant women to inform any drug-associated risks for adverse developmental outcomes. Animal reproduction studies conducted with sildenafil did not show adverse developmental outcomes when administered during organogenesis in rats and rabbits at oral doses up to 16 and 32 times, respectively, the maximum recommended human dose (MRHD) of 100 mg/day on a mg/m 2 basis (see Data).

Data Animal Data No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits which received oral doses up to 200 mg/kg/day during organogenesis. These doses represent, respectively, about 16 and 32 times the MRHD on a mg/m 2 basis in a 50 kg subject. In the rat pre- and postnatal development study, the no observed adverse effect dose was 30 mg/kg/day given for 36 days, about 2 times the MRHD on a mg/m 2 basis in a 50 kg subject.

Mechanism of action

12.1 Mechanism of Action The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood.

Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum.

Sildenafil at recommended doses has no effect in the absence of sexual stimulation. Binding Characteristics Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, >80-fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11).

Sildenafil is approximately 4,000-fold more selective for PDE5 compared to PDE3. PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina which is involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision [see Clinical Pharmacology (12.2)].

In addition to human corpus cavernosum smooth muscle, PDE5 is also found in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle, brain, heart, liver, kidney, lung, pancreas, prostate, bladder, testis, and seminal vesicle. The inhibition of PDE5 in some of these tissues by sildenafil may be the basis for the enhanced platelet antiaggregatory activity of NO observed in vitro, an inhibition of platelet thrombus formation in vivo and peripheral arterial-venous dilatation in vivo.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Effects of VIAGRA on Erectile Response: In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (RigiScan ®), after VIAGRA administration compared with placebo. Most studies assessed the efficacy of VIAGRA approximately 60 minutes post dose.

The erectile response, as assessed by RigiScan ®, generally increased with increasing sildenafil dose and plasma concentration. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours. Effects of VIAGRA on Blood Pressure: Single oral doses of sildenafil (100 mg) administered to healthy volunteers produced decreases in sitting blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8.3/5.3 mmHg).

The decrease in sitting blood pressure was most notable approximately 1-2 hours after dosing, and was not different than placebo at 8 hours. Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg of VIAGRA, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4.1)].

Figure 1: Mean Change from Baseline in Sitting Systolic Blood Pressure, Healthy Volunteers. Effects of VIAGRA on Blood Pressure When Nitroglycerin is Subsequently Administered: Based on the pharmacokinetic profile of a single 100 mg oral dose given to healthy normal volunteers, the plasma levels of sildenafil at 24 hours post dose are approximately 2 ng/mL (compared to peak plasma levels of approximately 440 ng/mL).

In the following patients: age >65 years, hepatic impairment (e.g., cirrhosis), severe renal impairment (e.g., creatinine clearance <30 mL/min), and concomitant use of erythromycin or strong CYP3A4 inhibitors, plasma levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher than those seen in healthy volunteers. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [see Contraindications (4.1)].

Effects of VIAGRA on Blood Pressure When Co-administered with Alpha-Blockers: Three double-blind, placebo-controlled, randomized, two-way crossover studies were conducted to assess the interaction of VIAGRA with doxazosin, an alpha-adrenergic blocking agent. Study 1: VIAGRA with Doxazosin In the first study, a single oral dose of VIAGRA 100 mg or matching placebo was administered in a 2-period crossover design to 4 generally healthy males with benign prostatic hyperplasia (BPH).

Following at least 14 consecutive daily doses of doxazosin, VIAGRA 100 mg or matching placebo was administered simultaneously with doxazosin. Following a review of the data from these first 4 subjects (details provided below), the VIAGRA dose was reduced to 25 mg. Thereafter, 17 subjects were treated with VIAGRA 25 mg or matching placebo in combination with doxazosin 4 mg (15 subjects) or doxazosin 8 mg (2 subjects).

The mean subject age was 66.5 years. For the 17 subjects who received VIAGRA 25 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure (mmHg) VIAGRA 25 mg Supine 7.4 (-0.9, 15.7) Standing 6.0 (-0.8, 12.8) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 25 mg VIAGRA or matching placebo are shown in Figure 2.

Figure 2: Mean Standing Systolic Blood Pressure Change from Baseline Blood pressure was measured immediately pre-dose and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours after VIAGRA or matching placebo. Outliers were defined as subjects with a standing systolic blood pressure of <85 mmHg or a decrease from baseline in standing systolic blood pressure of >30 mmHg at one or more timepoints.

There were no subjects treated with VIAGRA 25 mg who had a standing SBP <85 mmHg. There were three subjects with a decrease from baseline in standing systolic BP >30 mmHg following VIAGRA 25 mg, one subject with a decrease from baseline in standing systolic BP >30 mmHg following placebo and two subjects with a decrease from baseline in standing systolic BP >30 mmHg following both VIAGRA and placebo.

No severe adverse events potentially related to blood pressure effects were reported in this group. Of the four subjects who received VIAGRA 100 mg in the first part of this study, a severe adverse event related to blood pressure effect was reported in one patient (postural hypotension that began 35 minutes after dosing with VIAGRA with symptoms lasting for 8 hours), and mild adverse events potentially related to blood pressure effects were reported in two others (dizziness, headache and fatigue at 1 hour after dosing; and dizziness, lightheadedness and nausea at 4 hours after dosing).

There were no reports of syncope among these patients. For these four subjects, the placebo-subtracted mean maximum decreases from baseline in supine and standing systolic blood pressures were 14.8 mmHg and 21.5 mmHg, respectively. Two of these subjects had a standing SBP <85 mmHg. Both of these subjects were protocol violators, one due to a low baseline standing SBP, and the other due to baseline orthostatic hypotension.

Study 2: VIAGRA with Doxazosin In the second study, a single oral dose of VIAGRA 50 mg or matching placebo was administered in a 2-period crossover design to 20 generally healthy males with BPH. Following at least 14 consecutive days of doxazosin, VIAGRA 50 mg or matching placebo was administered simultaneously with doxazosin 4 mg (17 subjects) or with doxazosin 8 mg (3 subjects).

The mean subject age in this study was 63.9 years. Twenty subjects received VIAGRA 50 mg, but only 19 subjects received matching placebo. One patient discontinued the study prematurely due to an adverse event of hypotension following dosing with VIAGRA 50 mg. This patient had been taking minoxidil, a potent vasodilator, during the study.

For the 19 subjects who received both VIAGRA and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure (mmHg) VIAGRA 50 mg (95% CI) Supine 9.08 (5.48, 12.68) Standing 11.62 (7.34, 15.90) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 50 mg VIAGRA or matching placebo are shown in Figure 3. Figure 3: Mean Standing Systolic Blood Pressure Change from Baseline Blood pressure was measured after administration of VIAGRA at the same times as those specified for the first doxazosin study.

There were two subjects who had a standing SBP of <85 mmHg. In these two subjects, hypotension was reported as a moderately severe adverse event, beginning at approximately 1 hour after administration of VIAGRA 50 mg and resolving after approximately 7.5 hours. There was one subject with a decrease from baseline in standing systolic BP >30 mmHg following VIAGRA 50 mg and one subject with a decrease from baseline in standing systolic BP >30 mmHg following both VIAGRA 50 mg and placebo.

There were no severe adverse events potentially related to blood pressure and no episodes of syncope reported in this study. Study 3: VIAGRA with Doxazosin In the third study, a single oral dose of VIAGRA 100 mg or matching placebo was administered in a 3-period crossover design to 20 generally healthy males with BPH. In dose period 1, subjects were administered open-label doxazosin and a single dose of VIAGRA 50 mg simultaneously, after at least 14 consecutive days of doxazosin.

If a subject did not successfully complete this first dosing period, he was discontinued from the study. Subjects who had successfully completed the previous doxazosin interaction study (using VIAGRA 50 mg), including no significant hemodynamic adverse events, were allowed to skip dose period 1. Treatment with doxazosin continued for at least 7 days after dose period 1.

Thereafter, VIAGRA 100 mg or matching placebo was administered simultaneously with doxazosin 4 mg (14 subjects) or doxazosin 8 mg (6 subjects) in standard crossover fashion. The mean subject age in this study was 66.4 years. Twenty-five subjects were screened. Two were discontinued after study period 1: one failed to meet pre-dose screening qualifications and the other experienced symptomatic hypotension as a moderately severe adverse event 30 minutes after dosing with open-label VIAGRA 50 mg.

Of the twenty subjects who were ultimately assigned to treatment, a total of 13 subjects successfully completed dose period 1, and seven had successfully completed the previous doxazosin study (using VIAGRA 50 mg). For the 20 subjects who received VIAGRA 100 mg and matching placebo, the placebo-subtracted mean maximum decreases from baseline (95% CI) in systolic blood pressure were as follows: Placebo-subtracted mean maximum decrease in systolic blood pressure (mmHg) VIAGRA 100 mg Supine 7.9 (4.6, 11.1) Standing 4.3 (-1.8,10.3) The mean profiles of the change from baseline in standing systolic blood pressure in subjects treated with doxazosin in combination with 100 mg VIAGRA or matching placebo are shown in Figure 4.

Figure 4: Mean Standing Systolic Blood Pressure Change from Baseline Blood pressure was measured after administration of VIAGRA at the same times as those specified for the previous doxazosin studies. There were three subjects who had a standing SBP of <85 mmHg. All three were taking VIAGRA 100 mg, and all three reported mild adverse events at the time of reductions in standing SBP, including vasodilation and lightheadedness.

There were four subjects with a decrease from baseline in standing systolic BP >30 mmHg following VIAGRA 100 mg, one subject with a decrease from baseline in standing systolic BP >30 mmHg following placebo and one subject with a decrease from baseline in standing systolic BP >30 mmHg following both VIAGRA and placebo. While there were no severe adverse events potentially related to blood pressure reported in this study, one subject reported moderate vasodilatation after both VIAGRA 50 mg and 100 mg.

There were no episodes of syncope reported in this study. Effect of VIAGRA on Blood Pressure When Co-administered with Anti-hypertensives: When VIAGRA 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.

Effect of VIAGRA on Blood Pressure When Co-administered with Alcohol: VIAGRA (50 mg) did not potentiate the hypotensive effect of alcohol (0.5 g/kg) in healthy volunteers with mean maximum blood alcohol levels of 0.08%. The maximum observed decrease in systolic blood pressure was -18.5 mmHg when sildenafil was co-administered with alcohol versus -17.4 mmHg when alcohol was administered alone.

The maximum observed decrease in diastolic blood pressure was -17.2 mmHg when sildenafil was co-administered with alcohol versus -11.1 mmHg when alcohol was administered alone. There were no reports of postural dizziness or orthostatic hypotension. The maximum recommended dose of 100 mg sildenafil was not evaluated in this study [see Drug Interactions (7.5)].

Effects of VIAGRA on Cardiac Parameters: Single oral doses of sildenafil up to 100 mg produced no clinically relevant changes in the ECGs of normal male volunteers. Studies have produced relevant data on the effects of VIAGRA on cardiac output. In one small, open-label, uncontrolled, pilot study, eight patients with stable ischemic heart disease underwent Swan-Ganz catheterization.

A total dose of 40 mg sildenafil was administered by four intravenous infusions. The results from this pilot study are shown in Table 3; the mean resting systolic and diastolic blood pressures decreased by 7% and 10% compared to baseline in these patients. Mean resting values for right atrial pressure, pulmonary artery pressure, pulmonary artery occluded pressure and cardiac output decreased by 28%, 28%, 20% and 7% respectively.

Even though this total dosage produced plasma sildenafil concentrations which were approximately 2 to 5 times higher than the mean maximum plasma concentrations following a single oral dose of 100 mg in healthy male volunteers, the hemodynamic response to exercise was preserved in these patients. Table 3. Hemodynamic Data in Patients with Stable Ischemic Heart Disease after Intravenous Administration of 40 mg of Sildenafil Means ± SD At rest After 4 minutes of exercise N Baseline (B2) n Sildenafil (D1) n Baseline n Sildenafil PAOP (mmHg) 8 8.1 ± 5.1 8 6.5 ± 4.3 8 36.0 ± 13.7 8 27.8 ± 15.3 Mean PAP (mmHg) 8 16.7 ± 4 8 12.1 ± 3.9 8 39.4 ± 12.9 8 31.7 ± 13.2 Mean RAP (mmHg) 7 5.7 ± 3.7 8 4.1 ± 3.7 - - - - Systolic SAP (mmHg) 8 150.4 ± 12.4 8 140.6 ± 16.5 8 199.5 ± 37.4 8 187.8 ± 30.0 Diastolic SAP (mmHg) 8 73.6 ± 7.8 8 65.9 ± 10 8 84.6 ± 9.7 8 79.5 ± 9.4 Cardiac output (L/min) 8 5.6 ± 0.9 8 5.2 ± 1.1 8 11.5 ± 2.4 8 10.2 ± 3.5 Heart rate (bpm) 8 67 ± 11.1 8 66.9 ± 12 8 101.9 ± 11.6 8 99.0 ± 20.4 In a double-blind study, 144 patients with erectile dysfunction and chronic stable angina limited by exercise, not receiving chronic oral nitrates, were randomized to a single dose of placebo or VIAGRA 100 mg 1 hour prior to exercise testing.

The primary endpoint was time to limiting angina in the evaluable cohort. The mean times (adjusted for baseline) to onset of limiting angina were 423.6 and 403.7 seconds for sildenafil (N=70) and placebo, respectively. These results demonstrated that the effect of VIAGRA on the primary endpoint was statistically non-inferior to placebo.

Effects of VIAGRA on Vision: At single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina.

Subjects in the study reported this finding as difficulties in discriminating blue/green. An evaluation of visual function at doses up to twice the maximum recommended dose revealed no effects of VIAGRA on visual acuity, intraocular pressure, or pupillometry. Effects of VIAGRA on Sperm: There was no effect on sperm motility or morphology after single 100 mg oral doses of VIAGRA in healthy volunteers.

Figure 1 Figure 2 Figure 3 Figure 4

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Metabolism and Excretion Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes.

After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics VIAGRA is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (range 25-63%). The pharmacokinetics of sildenafil are dose-proportional over the recommended dose range. It is eliminated predominantly by hepatic metabolism (mainly CYP3A4) and is converted to an active metabolite with properties similar to the parent, sildenafil.

Both sildenafil and the metabolite have terminal half lives of about 4 hours. Mean sildenafil plasma concentrations measured after the administration of a single oral dose of 100 mg to healthy male volunteers is depicted below: Figure 5: Mean Sildenafil Plasma Concentrations in Healthy Male Volunteers. Absorption and Distribution VIAGRA is rapidly absorbed.

Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When VIAGRA is taken with a high fat meal, the rate of absorption is reduced, with a mean delay in T max of 60 minutes and a mean reduction in C max of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the tissues.

Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations. Based upon measurements of sildenafil in semen of healthy volunteers 90 minutes after dosing, less than 0.001% of the administered dose may appear in the semen of patients.

Metabolism and Excretion Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is itself further metabolized. This metabolite has a PDE selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug.

Plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil’s pharmacologic effects. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).

Similar values for pharmacokinetic parameters were seen in normal volunteers and in the patient population, using a population pharmacokinetic approach. Pharmacokinetics in Special Populations Geriatrics Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (18-45 years).

Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively [see Dosage and Administration (2.5), and Use in Specific Populations (8.5)] Renal Impairment In volunteers with mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose of VIAGRA (50 mg) were not altered. In volunteers with severe (CLcr <30 mL/min) renal impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC and C max compared to age-matched volunteers with no renal impairment [see Dosage and Administration (2.5), and Use in Specific Populations (8.6)].

In addition, N-desmethyl metabolite AUC and C max values significantly increased by 200% and 79%, respectively in subjects with severe renal impairment compared to subjects with normal renal function. Hepatic Impairment In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in increases in AUC (85%) and C max (47%) compared to age-matched volunteers with no hepatic impairment.

The pharmacokinetics of sildenafil in patients with severely impaired hepatic function (Child-Pugh Class C) have not been studied [see Dosage and Administration (2.5) and Use in Specific Populations (8.7)]. Therefore, age >65, hepatic impairment and severe renal impairment are associated with increased plasma levels of sildenafil.

A starting oral dose of 25 mg should be considered in those patients [see Dosage and Administration (2.5)]. Drug Interaction Studies Effects of Other Drugs on VIAGRA Sildenafil metabolism is principally mediated by CYP3A4 (major route) and CYP2C9 (minor route). Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance.

The concomitant use of erythromycin or strong CYP3A4 inhibitors (e.g., saquinavir, ketoconazole, itraconazole) as well as the nonspecific CYP inhibitor, cimetidine, is associated with increased plasma levels of sildenafil [see Dosage and Administration (2.4)]. In vivo studies Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with VIAGRA (50 mg) to healthy volunteers.

When a single 100 mg dose of VIAGRA was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 160% increase in sildenafil C max and a 182% increase in sildenafil AUC. In addition, in a study performed in healthy male volunteers, co-administration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with VIAGRA (100 mg single dose) resulted in a 140% increase in sildenafil C max and a 210% increase in sildenafil AUC.

VIAGRA had no effect on saquinavir pharmacokinetics. A stronger CYP3A4 inhibitor such as ketoconazole or itraconazole could be expected to have greater effect than that seen with saquinavir. Population pharmacokinetic data from patients in clinical trials also indicated a reduction in sildenafil clearance when it was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine) [see Dosage and Administration (2.4) and Drug Interactions (7.4)].

In another study in healthy male volunteers, co-administration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg bid) with VIAGRA (100 mg single dose) resulted in a 300% (4-fold) increase in sildenafil C max and a 1000% (11-fold) increase in sildenafil plasma AUC. At 24 hours the plasma levels of sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone.

This is consistent with ritonavir’s marked effects on a broad range of P450 substrates. VIAGRA had no effect on ritonavir pharmacokinetics [see Dosage and Administration (2.4) and Drug Interactions (7.4)]. Although the interaction between other protease inhibitors and sildenafil has not been studied, their concomitant use is expected to increase sildenafil levels.

In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil C max. Concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma levels of sildenafil.

Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of VIAGRA. In healthy male volunteers, there was no evidence of a clinically significant effect of azithromycin (500 mg daily for 3 days) on the systemic exposure of sildenafil or its major circulating metabolite. Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers.

The AUC of the active metabolite, N-desmethyl sildenafil, was increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence. Effects of VIAGRA on Other Drugs In vitro studies Sildenafil is a weak inhibitor of the CYP isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 µM).

Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that VIAGRA will alter the clearance of substrates of these isoenzymes. In vivo studies No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9. In a study of healthy male volunteers, sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.

VIAGRA (50 mg) did not potentiate the increase in bleeding time caused by aspirin (150 mg). Sildenafil at steady state, at a dose not approved for the treatment of erectile dysfunction (80 mg t.i.d.) resulted in a 50% increase in AUC and a 42% increase in C max of bosentan (125 mg b.i.d.). Figure 5

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Viagra · Viatris Specialty LLC [US FDA-approved label, version 6, November 17, 2023]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d905dc8d-917f-4ea3-a4ee-a1ecf6967d4e
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .